Major Korean R&D-focused pharmaceutical company known for global licensing deals in diabetes/obesity and oncology drugs.
Major Korean R&D-focused pharmaceutical company known for global licensing deals in diabetes/obesity and oncology drugs.
Sells prescription drugs in Korea, often combination pills built from existing molecules, through hospitals and wholesalers; that steady business funds research. Licensing deals with larger drugmakers add lumpy milestone payments tied to partners' trial progress. Hanmi Science is the holding company above it.
Moat: narrow (IP / patents, brand). One of few Asian pharma companies with a globally licensed novel-drug pipeline.
Headquarters: Seoul, South Korea · Founded: 1973 · Employees: 2,382
Size HanmiPharm (128940.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $3.95B, the 89th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩438,500 on 18 Nov 2026.
Performance Over six months the shares fell 2.5%, against +3.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue grew 13.9% over the last twelve months (peer median +7.9%); the operating margin is 15.7% (peer median 19.4%).
Valuation It trades at 15.0× forward earnings against a peer median of 21.9× (3rd cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.9 points above its cost of capital (6.0% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.67T | ₩1.55T | ₩1.50T | ₩1.49T | ₩1.33T |
| Revenue growth | — | +3% | 0% | +12% | — |
| Gross profit | ₩982B | ₩880B | ₩827B | ₩836B | ₩730B |
| EBITDA | ₩362B | ₩323B | ₩310B | ₩323B | ₩250B |
| Net income | ₩189B | ₩170B | ₩121B | ₩146B | ₩82.8B |
| Free cash flow | ₩172B | ₩130B | ₩154B | ₩189B | ₩133B |
| Capital expenditure | ₩96.1B | ₩80.7B | ₩67.0B | ₩47.7B | ₩69.4B |
| Total debt | ₩385B | ₩434B | ₩497B | ₩573B | ₩678B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% |
| Yuhan 000100.KS | $4.11B | -10% | +8% | 6% | 40.4× | n/a |
| SKBP 326030.KS | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 128940.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.8% | +2.6% | 5th highest of 21 |
| 6-month return | -2.5% | +3.5% | 7th lowest of 19 |
| Distance from 52-week high | -32.0% | -23.4% | 8th lowest of 21 |
| Revenue growth (TTM) | +13.9% | +7.9% | 7th highest of 18 |
| Operating margin | 15.7% | 19.4% | 7th lowest of 17 |
| Forward P/E | 15.0× | 21.9× | 3rd cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 4.7% | 6.4% | 8th least demanding of 16 |
| Growth delivered (Del g) | +7.5% | +5.9% | 8th highest of 16 |
| Hurdle (Req g minus delivered) | -2.9 pp | -8.2 pp | 7th most demanding of 16 |
| ROIC minus cost of capital | +4.9 pp | +6.9 pp | 9th lowest of 18 |
| EV / EBITDA | 15.2× | 22.9× | 4th cheapest of 10 |
| Net debt / EBITDA | 0.2× | -0.3× | 4th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |